StockData
Zura Bio Ltd logo

Zura Bio Ltd (ZURA) company profile

ZURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 5/30
$0.95−0.01 (-1.32%)

Close on Nov 19, 2026Market cap $91.74MP/E –Yield –

About Zura Bio

Biological Products, (No Diagnostic Substances), SIC 2836

Zura Bio is a clinical-stage biotechnology company focused on developing therapies for individuals suffering from autoimmune and inflammatory disorders. The company’s pipeline comprises three licensed drug candidates: tibulizumab, a bispecific antibody designed to inhibit both IL-17A and BAFF; crebankitug, a monoclonal antibody targeting IL-7 receptor alpha; and torudokimab, a monoclonal antibody directed against IL-33. Rather than serving commercial customers, the firm evaluates its experimental treatments in adult clinical trial participants, with tibulizumab undergoing evaluation for hidradenitis suppurativa and diffuse cutaneous systemic sclerosis.

The company operates without dedicated in-house facilities, instead relying on contract manufacturers across Italy, the Netherlands, and the United Kingdom, alongside stability studies in China, to produce drug substance and drug product batches. Clinical studies take place across the United States, Canada, Europe, and Latin America, involving over three hundred targeted participants across active Phase 2 programs. The provided text does not identify the location of the corporate headquarters.

Summary of the business section of Zura Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Zura Bio Ltd
Headquarters
La Jolla, CA
Address
4225 Executive Square, Suite 600 92037
Phone
(858) 247-0520
Employees
40, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
E9
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, East Brunswick, New Jersey

Stock & identifiers

Ticker
ZURA
Former tickers
JATT until Mar 21, 2023
Exchange
Nasdaq
IPO date
Jul 14, 2021
Shares outstanding
96M, Oct 27, 2026
Public float
$58.99M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1855644
CUSIP
G9TY5A101
FIGI
BBG011FJXV49
Share class FIGI
BBG011FJXVZ5
LEI
549300LQXD6M2MIQFN24
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sandeep Chidambar KulkarniChief Executive Officer, Director–
Robert LisickiChief Executive Officer, Director–
Marlyn Teresa MathewVP, Principal Acctg. Officer129,182
Gary WhaleChief Technology Officer–
Eric J. HyllengrenChief Financial Officer–
Kim DavisChief Legal Officer493,881
Kiran NistalaSee Remarks3,195
Verender S. BadialChief Financial Officer517,519
Daniel J. BeckerDirector–
Mark EisnerDirector–
Ajay NirulaDirector–
Jennifer JarrettDirector–
Amit MunshiDirector777,384
Steven J. SchochDirector–
Parvinder ThiaraDirector0
van Amstel Arnout PloosDirector120,000
Neil Murray Hamilton GrahamDirector–
Someit SidhuDirector5,203,715

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Robert Lisicki
Former Chief Executive Officer
$624.00K–$1.12M–$1.74M-74%
Kim Davis
Chief Operating Officer, Chief Legal Officer and Corporate Secretary; Former Interim Chief Executive Officer
$486.36K$312.00K$474.09K$8.84K$1.28M-29%
Eric Hyllengren
Former Chief Financial Officer
$230.30K$95.00K$711.31K$11.88K$1.05M–
Kiran Nistala
Chief Medical Officer and Head of Development
$468.33K$213.41K$331.42K$9.41K$1.02M-60%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Jul 14, 2021
Offer price
$10.00
Securities offered
12,000,000
Gross proceeds
$120.00M
Exchange
NYSE
First trading day
Sep 3, 2021
First-day close
$9.70-3.0%
Lock-up ends (est.)
Mar 2, 2022

“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 40 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?